Patents by Inventor Priya Prakash
Priya Prakash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115692Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.Type: ApplicationFiled: July 12, 2023Publication date: April 11, 2024Inventors: Sean Michael SULLIVAN, Daiki MATSUDA, Kiyoshi TACHIKAWA, Padmanabh CHIVUKULA, Priya Prakash KARMALI, Jared Henry DAVIS, Yanjie BAO
-
Publication number: 20240115691Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.Type: ApplicationFiled: June 30, 2023Publication date: April 11, 2024Inventors: Sean Michael SULLIVAN, Daiki MATSUDA, Kiyoshi TACHIKAWA, Padmanabh CHIVUKULA, Priya Prakash KARMALI, Jared Henry DAVIS, Yanjie BAO, Amit SAGI
-
Patent number: 11938227Abstract: A method of producing lipid-encapsulated RNA nanoparticles includes flowing an aqueous solution comprising an RNA through a 1st tube having a first inner diameter (ID); the RNA comprises from about 6,000 to about 13,000 nucleotides; flowing an ethanol solution comprising lipids through a 2nd tube having a second inner diameter (ID), at a flow rate of about 0.2 to about 1 times relative to the aqueous solution through the 1st tube, the lipids comprise a cationic lipid; and mixing the ethanol solution with the aqueous solution; the first ID and second ID and flow rates through the 1st tube and 2nd tube are selected to produce a shear force sufficiently low to preserve the integrity of the RNA; the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about ethanol, the lipid-encapsulated RNA nanoparticles having a bilayer structure.Type: GrantFiled: September 13, 2021Date of Patent: March 26, 2024Assignee: Arcturus Therapeutics, Inc.Inventors: Yanjie Bao, Brenda Clemente, Priya Prakash Karmali
-
Publication number: 20240089179Abstract: Technologies are provided for providing a dashboard interface corresponding to one or more datacenter components for information originating from one or more proprietary applications. A selection of information corresponding to the one or more datacenter components is initially received. Upon receiving the selection, an application programming interface (API) call request is made for the information corresponding to the one or more datacenter components from the one or more proprietary applications. As the information corresponding to one or more datacenter components from the one or more proprietary applications is received, it is aggregated and provided within the dashboard interface.Type: ApplicationFiled: November 20, 2023Publication date: March 14, 2024Inventors: Jithu M, Priyanka BANDARU, Sharaz KHAN, Akhil KR, Ajith PRAKASH, Prajot PATIL, Ravindra Sangamesh GADAD, Priya RAI, Asad IQBAL, Sujith SHETTY, Dhananjay GAWALI, Pravat SANTRA, John ULMER
-
Publication number: 20230323345Abstract: An oligomer comprising a sense strand and an antisense strand that mediates RNA interference against a target RNA sequence having a trinucleotide repeat expansion is provided, wherein the antisense strand is complementary to the target RNA sequence and comprises a sequence having at least 80% identity to the sequence of Formula (I): rGrCrUrGrCrUrGrCX1X2rCrUrGrCrUrGrCrUrG (I), wherein X1 and X2 are each independently selected from the group consisting of rA, rU, rG, rC, UNA-A, UNA-U, UNA-G, and UNA-C and wherein at least one of X1 and X2 is a UNA monomer; the oligomer comprises a UNA monomer at the first position at the 5?-end of the sense strand; and the sense strand and the antisense strand each independently include 19-29 monomers. The oligomers are useful as therapeutics targeting polyglutamine diseases and other diseases stemming from a trinucleotide repeat expansion.Type: ApplicationFiled: June 17, 2021Publication date: October 12, 2023Inventors: Kiyoshi TACHIKAWA, Angel I-Jou LEU, Padmanabh CHIVUKULA, Priya Prakash KARMALI
-
Publication number: 20230320995Abstract: Ionizable cationic lipids, methods for synthesizing them, as well as intermediates useful in synthesis of these lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is a LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.Type: ApplicationFiled: April 5, 2023Publication date: October 12, 2023Applicant: CAPSTAN THERAPEUTICS, INC.Inventors: Priya Prakash KARMALI, Steven TANIS
-
Publication number: 20230295081Abstract: The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof:Type: ApplicationFiled: November 10, 2022Publication date: September 21, 2023Inventors: Kumar RAJAPPAN, Steven TANIS, Amit SAGI, Priya Prakash KARMALI, Padmanabh CHIVUKULA
-
Patent number: 11759515Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.Type: GrantFiled: March 9, 2021Date of Patent: September 19, 2023Assignee: ARCTURUS THERAPEUTICS, INC.Inventors: Sean Michael Sullivan, Daiki Matsuda, Kiyoshi Tachikawa, Padmanabh Chivukula, Priya Prakash Karmali, Jared Henry Davis, Yanjie Bao
-
Patent number: 11744887Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.Type: GrantFiled: March 9, 2021Date of Patent: September 5, 2023Assignee: ARCTURUS THERAPEUTICS, INC.Inventors: Sean Michael Sullivan, Daiki Matsuda, Kiyoshi Tachikawa, Padmanabh Chivukula, Priya Prakash Karmali, Jared Henry Davis, Yanjie Bao, Amit Sagi
-
Patent number: 11709588Abstract: A method for providing a notification mechanism may include causing provision of a notification bar at an edge of a touch screen display in response to an occurrence of an event where the notification bar provides information indicative of the event, enabling, responsive to user input, extension of the notification bar away from the edge of the touch screen display to display one or more levels of other notification classes in addition to the information indicative of the event, causing presentation of the notification bar to remain in an extended position away from the edge of the touch screen display so as to display one or more levels of notification classes upon cessation of the user input and causing, responsive to exposure of each level that has a subsequent level thereafter, an indication of existence of the subsequent level. A corresponding apparatus and computer program product are also provided.Type: GrantFiled: February 8, 2018Date of Patent: July 25, 2023Assignee: NOKIA TECHNOLOGIES OYInventors: Priya Prakash, Antonio Pedro Rezendes, Guilherme Schneider, Laura Junkkonen
-
Publication number: 20230227826Abstract: A method for inhibiting expression of an mRNA having an expanded trinucleotide repeat region is provided comprising administering an oligomer comprising a sense strand and an antisense strand wherein: a) the antisense strand comprises a sequence of Formula (I): rGrCrUrGrCrUrGrCX1X2rCrUrGrCrUrGrCrUrG (I), wherein X1 and X2 are each independently selected from rA, rU, rG, rC, UNA-A, UNA-U, UNA-G, and UNA-C and wherein at least one of X1 and X2 is a UNA monomer; b) the oligomer comprises a UNA monomer at the first position at the 5?-end of the sense strand; and the sense strand and the antisense strand each independently include 19-29 monomers. The oligomer can be formulated in a lipid delivery vehicle, and can inhibit expression of Atrophin-1, Huntingtin, Ataxin-1, Ataxin-2, Ataxin-3, Ataxin-7, Alpha1A-voltage-dependent calcium channel subunit, TATA-box binding protein (TBP), Androgen Receptor, PP2A-PR55beta, FMR-1 Protein (FMRP), FMR-2 protein, Frataxin, Dystrophy Protein Kinase (DMPK), or Ataxin-8.Type: ApplicationFiled: June 17, 2021Publication date: July 20, 2023Inventors: Kiyoshi TACHIKAWA, Angel I-Jou LEU, Padmanabh CHIVUKULA, Priya Prakash KARMALI, Tomoki HIRUNAGI, Kentaro SAHASHI, Masahisa KATSUNO
-
Publication number: 20230219996Abstract: Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.Type: ApplicationFiled: July 29, 2022Publication date: July 13, 2023Inventors: Daiki MATSUDA, Sean Michael Sullivan, Kiyoshi Tachikawa, Padmanabh Chivukula, Priya Prakash Karmali, Yanjie Bao, Amit Sagi, Rajesh Mukthavaram
-
Publication number: 20230159449Abstract: Lipid formulations that encapsulate messenger RNA (mRNA) are provided herein. The mRNA can be used to express CFTR protein in vitro or in vivo. The lipid formulations can be administered via inhalation to treat cystic fibrosis.Type: ApplicationFiled: November 3, 2022Publication date: May 25, 2023Inventors: Carlos G. PEREZ-GARCIA, Kiyoshi TACHIKAWA, Daiki MATSUDA, Padmanabh CHIVUKULA, Priya Prakash KARMALI, Yanjie BAO, Jerel Boyd Lee VEGA, Rajesh MUKTHAVARAM, Amit SAGI, Yihua PEI
-
Publication number: 20220389422Abstract: The present disclosure describes compounds of Formula (I) or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are each independently (CH3(CH2)m)2CH—, (CH3(CH2)m)(CH3(CH2)m-1)CH, (CH3(CH2)m)(CH3(CH2)m-2)CH, (CH3(CH2)m)2CHCH2—, or (CH3(CH2)m)(CH3(CH2)m-1)CHCH2—, wherein m is 4-11; L1 and L2 are each independently absent, a linear C1-5 alkylene, or (CH2)p—O—(CH2)q, wherein p and q are each independently 1-3; R3 is a linear C2-5 alkylene optionally substituted with one or two methyl groups; R4 and R5 are each independently H or C1-6 alkyl; X is O or S; and n is 0-2.Type: ApplicationFiled: May 5, 2022Publication date: December 8, 2022Inventors: Kumar RAJAPPAN, Steven TANIS, Amit SAGI, Priya Prakash KARMALI
-
Publication number: 20220378702Abstract: Peptides and Peptide-lipid conjugates are provided in which the peptide has the general Formula (I) wherein, A1 is selected from serine, threonine, O—C1-6 alkyl serine, and O—C1-6 alkyl threonine; A2 is selected from serine, threonine, O—C1-6 alkyl serine, and O—C1-6 alkyl threonine; A3 is selected from glutamic acid, glutamine, asparagine, and aspartic acid; A4 is proline; each A5 is independently selected from a natural or modified amino acid; The peptide-lipid conjugates can be used in lipid formulations for the delivery of nucleic acids.Type: ApplicationFiled: May 5, 2022Publication date: December 1, 2022Inventors: Kumar Rajappan, Steven Tanis, Rajesh Mukthavaram, Amit Sagi, Priya Prakash Karmali, Padmanabh Chivukula
-
Publication number: 20220370624Abstract: A lipid composition containing a nucleic acid, wherein the lipid composition comprises a peptide-lipid conjugate, is provided. The peptide of the peptide-lipid conjugates can be from 4 to 52 amino acids in length. Methods of using the lipid composition in the in vivo delivery of nucleic acids are further provided.Type: ApplicationFiled: May 5, 2022Publication date: November 24, 2022Inventors: Kumar Rajappan, Steven Tanis, Rajesh Mukthavaram, Amit Sagi, Priya Prakash Karmali, Padmanabh Chivukula
-
Publication number: 20220168234Abstract: A method of producing lipid-encapsulated RNA nanoparticles includes flowing an aqueous solution comprising an RNA through a 1st tube having a first inner diameter (ID); the RNA comprises from about 6,000 to about 13,000 nucleotides; flowing an ethanol solution comprising lipids through a 2nd tube having a second inner diameter (ID), at a flow rate of about 0.2 to about 1 times relative to the aqueous solution through the 1st tube, the lipids comprise a cationic lipid; and mixing the ethanol solution with the aqueous solution; the first ID and second ID and flow rates through the 1st tube and 2nd tube are selected to produce a shear force sufficiently low to preserve the integrity of the RNA; the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about ethanol, the lipid-encapsulated RNA nanoparticles having a bilayer structure.Type: ApplicationFiled: September 13, 2021Publication date: June 2, 2022Inventors: Yanjie BAO, Brenda CLEMENTE, Priya Prakash KARMALI
-
Publication number: 20220162225Abstract: The present invention generally relates to a composition matter useful for diagnosis and treatment of Alzheimer's disease comprising A-L-F or a pharmaceutically acceptable salt thereof, wherein A is beta-amyloid peptide or a fragment thereof, L is an optional linker and F is a pH-responsive fluorophore, dye, or a therapeutic agent. Composition matters, methods of use as well as a kit for diagnosis and/or treatment of Alzheimer's disease are within the scope of this disclosure.Type: ApplicationFiled: March 27, 2020Publication date: May 26, 2022Applicant: Purdue Research FoundationInventors: Gaurav CHOPRA, Krupal JETHAVA, Priya PRAKASH
-
Publication number: 20220047519Abstract: Methods of preparing lyophilized lipid nanoparticle-nucleic acid compositions are provided. The methods comprise preparing a suspension of lipid nanoparticles with a monosaccharide and one or more excipients selected from thiosulfate, potassium sorbate, sodium benzoate, and iodixanol. Lyophilized lipid nanoparticle-nucleic acid compositions and methods of reconstituting and administering the same are further provided.Type: ApplicationFiled: August 13, 2021Publication date: February 17, 2022Inventors: Amit SAGI, Yanjie BAO, Priya Prakash KARMALI
-
Publication number: 20220023442Abstract: Nucleotides encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein are provided herein. Also describe are mRNA constructs that can be used to express CFTR protein in vitro or in vivo. The mRNA constructs can be formulated in a lipid formulation and administered via inhalation to treat cystic fibrosis.Type: ApplicationFiled: April 30, 2021Publication date: January 27, 2022Inventors: Carlos G. Perez-Garcia, Kiyoshi Tachikawa, Daiki Matsuda, Padmanabh Chivukula, Priya Prakash Karmali, Yanjie Bao, Jerel Boyd Lee Vega, Rajesh Mukthavaram, Amit Sagi